By Michael Susin
NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment.
In premarket trading ADRs were up $2.44 to $4.98. However, ADRs are down more than 80% on a 52-week basis.
The U.K. company said final data from the study of its asset NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma showed a prolonged progression free survival, a positive disease control rate and a favorable safety profile.
The company said that nine of the 12 patients achieved a disease control, including a patient who achieved a 55% reduction in tumor volume. Seven of them had a progression free survival time of greater than five months, which is highly atypical in this patient population, the company added.
"Outcomes in this patient population are very poor, with median progression free survival of two to three months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression free survival of more than five months," Chief Executive Hugh Griffith said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 16, 2024 06:18 ET (10:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.